In an oxaliplatin treatment test using patient‐derived xenograft (PDX) models with p53 WT, the group with lower levels of RFNG pS255 exhibited significant sensitivity to oxaliplatin chemotherapy (Figure 7O; Figure S7D, Supporting Information), suggesting that an appropriate context was necessary for selecting oxaliplatin treatment in CRC patients. Here, TP53 is linked to colorectal carcinoma.